Innorna Receives FDA Clearance for First-in-Class mRNA Therapy IN026 Targeting Refractory Gout
Key Insights
Innorna (search) announced FDA clearance of its IND application for IN026 (search), a potential first-in-class mRNA therapy for refractory gout (search) that delivers urate oxidase to the liver for systemic uric acid breakdown.
The IND clearance enables initiation of a Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026 (search) in patients with refractory gout (search).
Refractory gout (search) affects approximately 1.9 million people worldwide in 2026, representing about 3% of all gout (search) patients who experience frequent flares despite standard treatments.
Innorna (search), a clinical-stage biotech company advancing RNA medicines, has received FDA clearance for its Investigational New Drug (IND) application for IN026 (search), marking a significant milestone in the development of mRNA-based therapies for chronic metabolic diseases. The investigational treatment represents a potential first-in-class mRNA therapy specifically designed to address refractory gout (search), a severely debilitating condition affecting approximately 1.9 million people worldwide.
Novel mRNA Approach to Uric Acid Management
IN026 (search) delivers mRNA encoding urate oxidase (uricase; UOX (search)) directly to the liver, where the expressed enzyme facilitates systemic uric acid breakdown. This mechanism of action represents a departure from existing biologic treatments, which are limited by immunogenicity, tolerability challenges, and diminishing efficacy over time.
"Refractory gout (search) remains a severely debilitating condition, and existing biologic treatments are limited by immunogenicity, tolerability challenges, and diminishing efficacy over time. We are proud to advance IN026 (search) into clinical development as a potential first-in-class investigational mRNA therapeutic designed to overcome these limitations," said Michael Beckert, Chief Medical Officer of Innorna (search).
The therapy is engineered on Innorna (search)'s proprietary mRNA-lipid nanoparticle (LNP) platform, specifically designed for repeat administration and long-term disease control. This platform approach distinguishes IN026 (search) from traditional protein replacement therapies by potentially offering sustained therapeutic effects through repeated dosing.
Addressing Substantial Unmet Medical Need
Refractory or difficult-to-treat gout (search) refers to patients who continue to experience frequent flares, progressive tophi, or cannot achieve target serum urate levels despite guideline-directed urate-lowering therapy. This patient population represents a substantial unmet medical need, comprising approximately 3% of all gout patients globally.
The FDA clearance enables Innorna (search) to initiate a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026 (search) in this currently underserved patient population.
Platform Innovation for Chronic Disease Management
Dr. Linxian Li, Founder and CEO of Innorna (search), emphasized the broader implications of this development: "We founded Innorna on the conviction that mRNA, as a new modality, can achieve what existing therapeutic approaches cannot. With IN026 (search) advancing into clinical development, we are pioneering a new chapter for mRNA-based protein-replacement therapies engineered for repeated administration and long-term control of chronic diseases."
The company's approach represents an expansion of mRNA technology beyond its established applications in vaccines and acute treatments, potentially opening new therapeutic avenues for chronic metabolic conditions requiring long-term management.
Company Platform and Pipeline
Innorna (search) has built a proprietary RNA delivery and engineering platform featuring a rationally designed library of over 6,000 chemically diverse ionizable lipids, targeted LNP delivery systems, and mRNA technologies. The company's vertically integrated capabilities span from discovery through cGMP manufacturing, enabling accelerated development and capital efficiency.
The company is advancing a robust mRNA pipeline across chronic disease therapeutics, in vivo immunotherapies, and vaccines. Innorna (search) has raised $150 million to date and reports being well capitalized through key clinical milestones, while continuing to explore strategic financing and partnership opportunities to accelerate its broader programs.